BellRing Brands BRBR 深 沪
等待开盘 10-30 09:30:00 美东时间
30.84
-0.750
-2.37%
华盛通- 最 高31.92
- 今 开31.46
- 成交量 302.56万股
- 最 低 30.81
- 昨 收 31.59
- 总市值 38.86亿
- 52周最高 80.67
- 市盈率 静 16.55
- 换手率 2.40%
- 52周最低 30.44
- 委 比 32.01%
- 总股本 1.26亿
- 历史最高 80.67
- 量 比 0.97
- 振 幅 3.51%
- 历史最低 13.56
- 每 手 1
- 风险率 15.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BellRing Brands, Inc. (NYSE:BRBR) Doing What It Can To Lift Shares
毫不夸张地说，BellRing Brands, Inc.（纽约证券交易所代码：BRBR）目前17.6倍的市盈率（或“P/E”）看起来与美国市场相比相当“中规中矩...
10-29 02:04
BellRing Brands Announces Timing of Fiscal Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call
BellRing Brands, Inc. announced it will release its Q4 and FY2025 financial results and FY2026 outlook on November 18, 2025, at 7:00 a.m. ET, followed by a conference call at 8:30 a.m. ET. Darcy H. Davenport, CEO, and Paul A. Rode, CFO, will discuss the results. Interested parties can join the call via registration or listen to the webcast on BellRing’s website. A replay will also be available.
10-28 21:00
美股大行评级 | 升至45美元！英特尔获多家机构上调目标价；大摩上调拖拉机供应公司(TSCO)评级至"标配"，目标价升至60美元
今日重点评级关注：HC Wainwright & Co.：维持Alto Neuroscience"买入"评级，目标价从10美元升至50美元；RBC Capital：维持Precision Drilling"跑赢大市"评级，目标价从110美元升至117美元
10-27 09:45
美股大行评级 | 上调目标价！特斯拉、赛默飞世尔、拉姆研究、波士顿科学、安诺电子、金沙集团等获众多机构评级
今日重点评级关注：摩根士丹利：维持Viking Therapeutics"超配"评级，目标价从98美元升至102美元；摩根大通：维持IDEAYA Biosciences"超配"评级，目标价从74美元升至79美元
10-24 09:51
BellRing Brands Reaches Settlement in Joint Juice Lawsuit
An update from BellRing Brands ( ($BRBR) ) is now available. BellRing Brands‘ s...
10-24 05:02
Bernstein Initiates Coverage On BellRing Brands with Outperform Rating, Announces Price Target of $46
Bernstein analyst Alexia Howard initiates coverage on BellRing Brands (NYSE:BRBR) with a Outperform rating and announces Price Target of $46.
10-23 22:07
美股大行评级 | 潜在涨幅334.0%！HC Wainwright & Co.上调Inventiva目标价至24美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Inventiva"买入"评级，目标价从20美元升至24美元；摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从116美元升至119美元
10-10 11:36
美股大行评级 | 最高186美元！戴尔科技或多家机构上调目标价； 高盛上调超微公司目标价至210美元
今日重点评级关注：富国银行：维持Kyverna Therapeutics"超配"评级，目标价从24美元升至27美元；Chardan Capital：维持Oculis Holding"买入"评级，目标价从33美元升至51美元
10-09 10:51
UBS Maintains Neutral on BellRing Brands, Lowers Price Target to $39
UBS analyst Peter Grom maintains BellRing Brands (NYSE:BRBR) with a Neutral and lowers the price target from $40 to $39.
10-09 00:08
BellRing Brands Board Approves $400M Share Repurchase Over Next Two Years Starting September 2, 2025
BellRing Brands, Inc. (NYSE:BRBR) today announced its Board of Directors approved a $400 million share repurchase authorization over the next two years with share repurchases under the new authorization beginning on
09-02 20:03
